{"id":"copaxone-teva","safety":{"commonSideEffects":[{"rate":"~90%","effect":"Injection site reactions (erythema, induration, pain)"},{"rate":"~5-10%","effect":"Lipoatrophy at injection sites"},{"rate":"~5%","effect":"Systemic post-injection reaction (flushing, chest tightness, dyspnea)"},{"rate":"~10%","effect":"Headache"},{"rate":"~5%","effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL6068343","moleculeType":"Small molecule","molecularWeight":"402.74"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glatiramer acetate mimics myelin basic protein and acts as a decoy antigen, shifting the immune response from pro-inflammatory Th1 cells toward anti-inflammatory Th2 and regulatory T cells. This reduces attack on myelin-producing oligodendrocytes in the central nervous system. The mechanism also involves bystander suppression, where activated regulatory cells reduce inflammation more broadly.","oneSentence":"Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell activity in multiple sclerosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:22.739Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Clinically isolated syndrome (CIS) with high risk of MS"}]},"trialDetails":[{"nctId":"NCT02753088","phase":"PHASE3","title":"Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":158},{"nctId":"NCT01489254","phase":"PHASE3","title":"Efficacy and Safety of GTR in Comparison to Copaxone®","status":"COMPLETED","sponsor":"Synthon BV","startDate":"2011-10","conditions":"Multiple Sclerosis","enrollment":794},{"nctId":"NCT02023424","phase":"PHASE1","title":"An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2014-01","conditions":"Rett Syndrome","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glatiramer acetate"],"phase":"phase_3","status":"active","brandName":"Copaxone-Teva","genericName":"Copaxone-Teva","companyName":"Biocad","companyId":"biocad","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell activity in multiple sclerosis. Used for Relapsing-remitting multiple sclerosis (RRMS), Clinically isolated syndrome (CIS) with high risk of MS.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}